NDA 221075 · Bristol Myers Squibb
Zenbexus
Iberdomide Hydrochloride · Oral
NovelPriority reviewOrphanCDER novel approval, Aug 13, 2026: To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent
Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Aug 13, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
54
6 Phase 3, 16 recruiting
FAERS reports
149
143 serious, 12 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: EMBRYO-FETAL TOXICITY and SERIOUS VENOUS AND ARTERIAL THROMBOEMBOLISM EMBRYO-FETAL TOXICITY ZENBEXUS is contraindicated in pregnancy. ZENBEXUS is embryo-fetal toxic in animals and can cause birth defects or embryo-fetal death in humans. In females of reproductive potential, obtain 2 negative pregnancy tests before starting ZENBEXUS treatment [ Contraindications (4) , see Warnings and Precautions (5.1) and Use in Specific Populations (8.1 , 8.3) ] . Females of reproductive potential must use 2 effective forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after last dose of ZENBEXUS treatment [see Contraindications (4) , Warnings and Precautions (5.1) , and Use in Specific Populations (8.1 , 8.3) ] . Because of the risk of embryo-fetal toxicity, ZENBEXUS is only available through a restricted distribution program called ZENBEXUS REMS [see...
What it is approved for
From the label in effect Aug 13, 2026.
ZENBEXUS is indicated, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete response (CR) at any time [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ZENBEXUS is a cereblon-modulating protein degrader indicated in combination with daratumumab and hyaluronidase-fihj and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. (1) This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete response (CR) at any time. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Mechanism: Iberdomide is a cereblon-modulating protein degrader that binds to cereblon, a substrate recognition component of an E3 ubiquitin ligase complex. Iberdomide engages cereblon and facilitates recruitment, ubiquitination, and proteasomal degradation of the transcription factors, Aiolos and Ikaros, resulting in anti‑tumor and immunomodulatory activity. In vitro and in vivo, iberdomide treatment showed anti-tumor activity in multiple myeloma (MM) cells and xenografts including in lenalidomide- and pomalidomide-resistant MM cell lines. Immunomodulatory properties of iberdomide include increased...
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 13, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelMedication Guide
2 products under this application
- ZENBEXUS · IBERDOMIDE HYDROCHLORIDE EQ 1MG BASE · CAPSULE, ORAL · Prescription
- ZENBEXUS · IBERDOMIDE HYDROCHLORIDE EQ 0.75MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Iberdomide" as an intervention, any sponsor and status, largest first.
- A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple MyelomaPivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05827016 · 1,230 participants · Start Jun 22, 2023 · Primary completion Mar 15, 2029
Drug: Iberdomide; Lenalidomide · For: Multiple Myeloma
Sites: Aurora, Colorado; Jacksonville, Florida; Tampa, Florida · 269 sites in all
- Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Pivotal-lookingActive, not recruiting
CelgeneBristol Myers Squibb (BMY)
NCT04975997 · 939 participants · Start Jun 23, 2022 · Primary completion Nov 16, 2027
Drug: Dexamethasone; Daratumumab and 6 more · For: Multiple Myeloma
Sites: Hot Springs, Arkansas; Cerritos, California; Fountain Valley, California · 259 sites in all
- MInimal Residual Disease Adapted StrategyPivotal-lookingActive, not recruiting
Intergroupe Francophone du MyelomeResearch network
NCT04934475 · 791 participants · Start Dec 8, 2021 · Primary completion Sep 30, 2024
Drug: Isatuximab · For: Multiple Myeloma
Sites: Brussels, Belgium; Charleroi, Belgium; Haine-Saint-Paul, Belgium · 73 sites in all
- D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMMPivotal-lookingRecruiting
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT07624513 · 720 participants (planned) · Start Aug 31, 2026 · Primary completion Oct 1, 2033
Drug: Isatuximab; Iberdomide and 4 more · For: Multiple Myeloma
Sites: Boston, Massachusetts · 3 sites in all
AbbVieAbbVie (ABBV)
NCT06892522 · 602 participants (planned) · Start Jun 30, 2025 · Primary completion Dec 2035
Drug: Etentamig; Lenalidomide and 9 more · For: Multiple Myeloma
Sites: Duarte, California; Irvine, California; San Francisco, California · 36 sites in all
- NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-IberdomidePivotal-lookingRecruiting
PETHEMA FoundationAcademic, hospital or other
NCT05558319 · 480 participants (planned) · Start Nov 10, 2022 · Primary completion Apr 2027
Drug: Bortezomib; Isatuximab and 3 more · For: Newly Diagnosed Multiple Myeloma
Sites: Alcalá de Henares, Spain; Pozuelo de Alarcón, Spain; Pamplona, Spain · 68 sites in all
- A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple MyelomaPivotal-lookingActive, not recruiting
CelgeneBristol Myers Squibb (BMY)
NCT02773030 · 466 participants · Start Oct 14, 2016 · Primary completion May 9, 2024
Drug: CC-220; Dexamethasone and 6 more · For: Multiple Myeloma
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Atlanta, Georgia · 162 sites in all
- Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple MyelomaPivotal-lookingActive, not recruiting
University of Heidelberg Medical CenterAcademic, hospital or other
NCT06216158 · 411 participants (planned) · Start Apr 5, 2024 · Primary completion Dec 2028
Drug: Iberdomide; Isatuximab and 1 more · For: Multiple Myeloma
Sites: Krems, Austria; Linz, Austria; Salzburg, Austria · 69 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- febrile neutropenia22
- neutropenia19
- pneumonia13
- thrombocytopenia12
- covid-1911
- plasma cell myeloma10
- infection8
- fatigue7
- mixed liver injury7
- rash7
- anaemia6
- phlebitis6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 4 |
| 2021 | 6 |
| 2022 | 20 |
| 2023 | 64 |
| 2024 | 11 |
| 2025 | 21 |
| 2026 | 23 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.
Merrill JT, Werth VP, Furie R, et al. · N Engl J Med 2022 · Clinical Trial, Phase II, Multicenter Study
- Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial.
Lonial S, Popat R, Hulin C, et al. · Lancet Haematol 2022 · Clinical Trial, Phase II, Clinical Trial, Phase I
- Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial.
Lonial S, Dimopoulos MA, Gavriatopoulou M, et al. · Lancet Oncol 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- A Phase I, Open-Label, Mass Balance Study of [14C]-Iberdomide in Healthy Subjects.
Cheng Y, Wang X, Liu L, et al. · Eur J Drug Metab Pharmacokinet 2024 · Clinical Trial, Phase I
- Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse.
Touzeau C, Leleu X, Tiab M, et al. · Br J Haematol 2025 · Clinical Trial, Phase II, Multicenter Study
- Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma.
Amatangelo M, Flynt E, Stong N, et al. · Cell Rep Med 2024 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.